rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Twenty-four patients with chronic renal failure, stabilized on hemodialysis, were treated with recombinant human erythropoietin. Before treatment, all patients were anemic (mean Hct = 23.7%). Hematocrits reached normal levels (36.5%) after three months of treatment. Brain event-related potentials and neuropyschological tests were used to assess changes in brain and cognitive functions associated with the correction of anemia. Assessments were done prior to and after three and twelve months of rHuEPO treatment. The P3 component of the event-related potential increased in amplitude significantly with treatment, while its latency was unaffected. Of the four neuropsychological tests administered, scores on two improved significantly with treatment, and the other two approached significance.
The persistence of at least mild neurobehavioral impairments, despite clinically adequate dialysis therapy, suggests that factors other than uremic toxins per se might affect the brain of a uremic patient. Both elevated parathyroid hormone and aluminum levels have thus been implicated [12, 13] . Since anemia is almost always present in patients with ESRD and is severe enough to affect cerebral oxygen delivery [14] , we hypothesized that anemia is a contributor to the neurobehavioral dysfunction of uremia and that correction of anemia with rHuEPO in anemic stable CHD patients can minimize neurobehavioral dysfunction.
Event-related potentials (ERPs) have been shown to be sensitive, non-invasive and relatively objective indices of certain aspects of cognitive functioning. In particular, the later "endogenous" components (such as, N2 and P3; Fig. 1 ) are so named because they tend to vary in amplitude and latency as a function of subject variables such as attention, processing effort, stimulus evaluation and degree of certainty. In contrast, earlier components (such as, P1, Nl, and P2; Fig. 1 ) are termed "exogenous" because they vary in amplitude and latency as a function of stimulus parameters such as intensity and repetition rate. Among the currently identified endogenous components the P3 has been the most extensively studied [15, 16] . P3 latency has been found to reflect stimulus evaluation time, that is, the time it takes to identify, categorize and discriminate stimuli [17] [18] [19] [20] [21] , and is thus a measure of the rapidity of information processing. P3 latency increases with task complexity or discriminative difficulty [22] [23] [24] [25] [26] and with age [27] [28] [29] [30] [31] [32] , presumably reflecting cognitive slowing. In addition, a number of studies have shown significant latency increases in patients with dementia of various etiologies [33] [34] [35] [36] [37] [38] [39] . Finally, P3 latency has been found to be prolonged in many dialysis patients [40] . A previous study from this laboratory [41] found that for renal patients receiving hemodialysis, the latency of P3 elicited by a simple discrimination task was significantly greater than that of controls or patients on peritoneal dialysis.
P3 amplitude, on the other hand, varies with attention, with the amount of information extracted from a stimulus, and with certainty or closure [16, 42, 43] . No P3 is elicited by stimuli which are not attended to or processed in some way. Schizophrenics [44] , children with Attention Deficit Disorder [45, 46] , and chronic alcoholics [47] consistently show reduced P3 amplitudes as compared to controls. Problems with the regulation and maintenance of sustained attention are common features of these conditions. Normal subjects confronted with difficult discriminations which produce uncertainty as to their decisions show reductions of P3 amplitude [42, 48] , and P3 amplitude is also reduced when attention must be divided among two tasks [49] .
Neuropsychological tests are designed to test various aspects of cognitive functioning: attention, perception, learning, memory, language, motor skills, and executive functions (such as, organization, planning and mental flexibility) [50] . Many neuropsychological tests provide normative data so that an individual's performance can be compared with that of a normal group of the same age and education. Studies of groups of stable CHD patients have consistently found mild to moderate cognitive performance abnormalities on measures of memory and learning, attention and concentration, and speeded perceptual-motor tasks which require shifting cognitive sets or mental manipulation [5] [6] [7] [8] 11] .
The aim of this study was to assess the effects of rHuEPO treatment on the efficiency of cognitive functioning using both electrophysiological and neuropsychological measures.
Methods

Subjects
The subjects of this study were 24 patients (12 male, 12 female) with ESRD, currently on center hemodialysis (CHD). Their original disease diagnoses were chronic glomerulonephri-tis (N = 7), obstructive uropathy (N = 5), diabetic nephropathy (N = 4), and other/uncertain (N = 8). Their mean age was 46.8 16 years. All were receiving hemodialysis three times weekly during their participation in this study. The mean duration since onset of dialysis was 75.7 64 months. All had some degree of anemia with a group mean hematocrit level of 23.7 4%.
All patients were anephric. Dialysis was performed thrice weekly using cellophane-based hollow-fiber dialyzers and a glucose-containing bicarbonate bath. Dialysate potassium and calcium content varied, depending on individual patient needs. Dialysis was prescribed to achieve a KT/V (urea) of 1.0 to 1.2 [51] with a PCR of at least 0.8 g/kg/day. This was assessed on a quarterly basis and the dialysis prescription was adjusted to keep the KT/V constant over the course of the study.
Electrophysiological assessment
An auditory "oddball" detection task was used for the collection of electrophysiological data. Subjects listened to brief (50 msec) 390 Hz, 70 db SPL tone bursts presented through earphones at a rate of 1 per 1.5 seconds. These tones were occasionally (20% of trials) and randomly replaced by tone bursts of higher frequency (460 Hz) and intensity (84 db SPL). Subjects were instructed to ignore the frequent tones and keep a silent cumulative count of the rare, target tones. Stimulus presentation was occasionally interrupted to obtain the subject's current count of targets. This task continued until 32 artifact-free responses were obtained to target tones and 128 to frequent tones. Except for the moderate memory load, this oddball detection task is very simple, since the target and P3 P1 P2 FZ I r I frequent tones differ in both intensity and frequency, providing a double discrimination cue.
Neuropsychological assessment Four measures were utilized for neuropsychological assessment. The Trail Making Test Part B (TMTB) [521 requires that the subject connect with lines, in a given sequence, circled digits and letters randomly distributed on a page. The prescribed sequence is from I to A to 2 to B to 3 to C, etc.
Performance is scored in terms of time to complete the task correctly. The TMTB assesses attention, visual scanning, psychomotor speed, ability to sequence, and ability to shift cognitive set.
The Symbol Digit Modalities Test (SDMT) [53] requires matching of printed abstract symbols with a specific digit according to a key which provides the symbol-number match. Performance is scored in terms of the number of items correctly completed in a specified time. The SDMT measures learning, memory, psychomotor speed and scanning efficiency.
The Controlled Oral Word Association Test (COWAT) [54] involves the generation of as many words beginning with a designated letter (such as, F, A, or S) as the subject can within a specified time period. This task is repeated three times using different letters. Performance is scored in terms of the total number of words generated. Verbal fluency, planning and organization and retrieval from semantic memory are measured by the COWAT. For the Rey Auditory-Verbal Learning Test (RAVLT) [55] , the subject learns a list of 15 simple, unrelated words over five trials. A second list of 15 different words is then given and thereafter the subject must recall the words from the original list. For this study, a summary score of total number of words recalled on trials 1 to 5 was employed. The RAVLT evaluates verbal learning, immediate memory and retrieval from longterm storage after interference.
These tests were selected to measure cognitive functions known to be impaired in renal patients stabilized on dialysis, [5, 7] that is, speeded perceptual-motor tasks requiring flexibility of thinking and mental manipulation, as well as tests of learning and memory.
Electrophysiological methods
Subjects were prepared for recording by affixing electrodes in a midline array at parietal (Pz), central (Cz), and frontal (Fz) sites. Electrodes on both earlobes served as reference and ground, respectively. Care was taken to achieve electrode impedances below 5 kilohms. The subject was then seated in a sound attenuating recording chamber and fitted with earphones.
The electrodes were connected to amplifiers in the adjoining room. A computer presented stimuli and averaged the amplified signals.
The EEG from the three recording electrodes was amplified (14, 140x), ifitered (0.1 to 50 Hz bandpass), and digitized (250 samples/sec). Digitizing was initiated 100 msec before stimulus onset (to provide baseline data) and continued for 900 msec thereafter. Each digitized single-trial ERP epoch was checked for artifacts by the computer, and any value that exceeded a preset amplitude criterion due to eyeblink or movement artifacts resulted in rejection of that epoch. The computer continued stimulus presentation until 32 artifact-free target and 128 frequent responses were accumulated. Target and frequent responses were averaged separately. Averaged responses were viewed on a CRT monitor to determine whether ERP components were clear and measurable. If they were not, the run was repeated. ERPs from two runs could be summed to increase signal to noise ratios.
The P3 wave of the ERP, our primary interest, was identified as the largest positive wave 280 msec or later after stimulus onset that was present in responses to the target (counted) stimuli and absent or considerably diminished in responses to the frequent (non-counted) stimuli. The latency of the P3 peak was identified as the latency of the maximum positive topographic field density within the range of a visually identified P3
(that is, the maximum of Pz + Cz + Fz). Thus, a single latency was measured taking into consideration the recordings at all three electrode sites. P3 amplitudes for Pz, Cz and Fz were obtained at this latency. Ni and P2 latencies and amplitudes were obtained using similar procedures and were measured from averaged ERPs to both target and frequent tones, since the exogenous Ni and P2 occur to both stimuli. ERPs, neuropsychological scores, and hematocrit values were analyzed using analyses of variance, (repeated measures ANOVA, BMD P2V), paired t•-tests for contrast measures, and Pearson correlations. Since preliminary P3 data analysis suggested that total length of time on dialysis might influence P3 change with rHuEPO treatment, that variable was included in the P3 ANOVAs: a between-subjects (duration) and withinsubjects (treatment by electrode) mixed effects ANOVA (BMD P2V).
Timing of studies
Subjects were administered all procedures three times: before rHuEPO treatment (Pre-T), after approximately three months of treatment (T + 3 mos) when hematocrit values had stabilized at criterion level (32% or above), and after 12 months of treatment (T + 12 mos). For each assessment, subjects were studied on a day following a regularly scheduled and completed dialysis run as closely as possible to 24 hours after the completion of the last dialysis, the time when cognitive and electrophysiological function is best during the dialysis treatment cycle [56] . Blood for chemical analysis was drawn just prior to the electrophysiological study, and the neuropsychological assessment was done afterwards.
All 24 subjects completed the first and second electrophysiological assessments, but two of the subjects did not complete the third (one received a renal transplant and the other was too ill). Nineteen of the 24 subjects completed the first and second neuropsychological assessments and 14 completed the third assessment. The other subjects were lost due to scheduling difficulties and refusals to participate. Participation required that subjects come to the center an additional day beyond the three required for dialysis treatment. This posed problems for some patients particularly since the lengthy neuropsychological tests were the last items administered. Some patients were unwilling or too fatigued to complete the total assessment, particularly for T + 12. Additional scheduling problems were created by changes in the personnel administering the neuropsychological tests. Table 1 shows the group mean laboratory and blood pressure values at the three assessment points. Hematocrit levels showed a highly significant increase (t = 16.11, P < 0.001) to normal levels after three months of rHuEPO treatment. Significant decreases in BUN (t = -3.74, P < 0.01) and creatinine (t = -2.87, P < 0.01) were observed after twelve months of 
ERP amplitude
The amplitude of the P3 wave increased significantly with rHuEPO treatment (F 4.09, P <0.024, Figs. 1, 2 and Table  2 ). The mean P3 amplitude for the three recording electrodes (Pz, Cz, Fz) showed the maximum increase with three months of rHuEPO treatment and no significant change thereafter.
Seventeen of 22 patients (77%) showed P3 amplitude increases from pre-treatment to 12 months of treatment. As shown in Figure 3 , the amplitude of P3 recorded at the Fz electrode was significantly smaller than that recorded at central and parietal leads (electrode effect: F = 7.68, P < 0.0015). While it appears from Figure 3 that the amplitude increase at Fz with rHuEPO treatment was greater than that recorded at Pz and Cz, the treatment by electrode interaction was not significant (F = 1.36, P < 0.25).
Duration of dialysis did have a significant overall effect on P3 amplitude (duration effect: F = 4.58, P < 0.045, Fig. 4 , Table 2 ), with those on dialysis less than 50 months having larger P3s than those on dialysis for more than 50 months at each of the three testing times. However, the treatment by duration interaction did not approach significance (F = 0.37, P < 0.69), that is, duration of dialysis did not affect the P3 amplitude increase with rHuEPO treatment.
To determine whether rHuEPO treatment had a selective effect on the amplitude of the endogenous P3 component or a more general effect on all components, the amplitudes of the earlier Ni and P2 exogenous components were measured. As shown in Figure 2 and Table 2 , treatment had a negligible effect on the amplitudes of Ni and P2. The Nl amplitude, averaged across electrodes and stimuli (frequent and target), showed less than 0.5 microvolt change with treatment. P2 values also showed less than 0.5 microvolt change. Treatment effects in the ANOVAS for Ni and P2 did not approach significance.
ERP latency rHuEPO treatment had no significant effect on P3 latency
(treatment effect: F = 0.26, P = NS, Table 2 ). Mean P3 latency changed less than 10 msec over the three assessment periods. No main effect of duration or duration by treatment interaction was found. After three months of treatment, 11 of 24 patients (46%) showed a decrease in P3 latency greater than 10 msec from pre-treatment values, six patients (25%) showed no change, and seven patients (29%) showed increases. These percentages were virtually unchanged after 12 months of treatment.
Similarly, the latencies of Ni and P2 were unaffected by rHuEPO treatment (Table 2 ). For Ni the mean latencies varied less than 2 msec over the pre-treatment and two treatment periods and for P2 less than 10 msec. Table 3 , the mean scores from the four neuropsychological measures showed improvement with rHuEPO treatment. After three months of treatment, the SDMT score increase was significant (t = 2.46, P < 0.025), while those for RAVLT (t = 1.55, P < 0.075) and COWAT (t = 1.60, P < 0.08) approached significance. After 12 months of treatment, the TMTB time to completion, which decreased only slightly at three months, showed a significant decrease, that is, improvement (t = -2.85, P < 0.025). The SDMT score showed further improvement (t = 3.22, P < 0.01), but the RAVLT (t = 1.85, P <0.09) and COWAT (t = 1.64, P <0.15) scores again failed to reach significance.
Neuropsychological measures As shown in
No significant correlations were obtained between any of the four neuropsychological measures and either P3 amplitude or P3 latency at the pre-treatment assessment or after three months of treatment. Correlations obtained for change scores, that is, three-month rHuEPO treatment values minus pretreatment values for the same P3 and neuropsychological variables, resulted in only one significant relationship. P3 latency change showed a negative correlation with COWAT change (r = -0.57, P < 0.015), indicating that as the number of words generated increased, P3 latency decreased. Because of the reduced sample size, correlations with twelve month values would not be comparable and are not reported.
Hematocrit values correlated significantly with P3 amplitude at the pre-treatment assessment (r = 0.46, P < 0.02), but showed no correlation after three months or 12 months of treatment. Similarly, change scores for Hct and P3 amplitude were uncorrelated. No significant correlations were obtained for Hct and P3 latency.
None of the neuropsychological test scores correlated with Hct values at the pre-treatment assessment. After three months of rHuEPO treatment, the only correlation obtained was with TMTB (r = -0.55, P < 0.015). No correlation was found for change scores.
In summary, rHuEPO treatment for the correction of anemia in renal patients stabilized on hemodialysis resulted in significant increase in P3 amplitude but no change in P3 latency, significant improvement on two of four neuropsychological tests and near significant improvement on two more. These changes suggest that EPO treatment improved sustained attention, enhancing performance on complex speeded perceptualmotor tasks requiring efficient scanning, mental manipulation and shifting of cognitive sets and, to a lesser extent, learning and memory.
Discussion
The increase in ERP amplitude produced by rHuEPO treatment was specific to the endogenous P3 component; the exogenous N 1 and P2 components were unaffected by treatment. This selective effect suggests that rHuEPO treatment did not have the sort of direct physiological effect on brain tissue that would produce greater neuronal excitability or lowered thresholds and thus increase the amplitude of all ERP components, as has been observed immediately following hemodialysis [57] . The specific effect on P3 amplitude together with the improvement in neuropsychological test scores points to changes in higher cognitive functions. However, P3 latency, a measure shown to be sensitive to such subtle impairments in brain function as occur early in the course of dementia [58] , did not decrease. This suggests that the improvement in neuropsychological test performance and the increase in P3 amplitude are the result of improvement in some aspect of attention [15] . As indicated at the outset, P3 amplitude is diminished in subjects who have problems with the maintenance of attention.
The largest increase in P3 amplitude with rHuEPO treatment was observed in recordings from the scalp electrode placed over the frontal brain region. While it cannot be assumed that a scalp electrode reflects only, or even primarily, brain activity in the region immediately underlying that electrode, and it is thought that the neural generators of the P3 wave are widely distributed throughout the brain [59-fill, it is nonetheless an interesting observation since the frontal lobes have an important role in the regulation of attention [62] . The fact that hematocrit values were significantly correlated with P3 amplitude before but not after EPO treatment provides additional support for the view that severe anemia may be a factor in the cognitive impairments noted in uremic patients.
That is, before treatment the degree to which a patient is anemic is related to diminished P3 amplitude, but once Hct is normalized, any relation with Hct disappears. Similar findings have recently been reported by Grimm et al [63] .
The lack of change in P3 latency with rHuEPO treatment was contrary to expectation, since P3 latency has been shown to be abnormally prolonged in many CHD patients [40] . Moreover, significant decrease in P3 latency with rHuEPO treatment was also a major finding in the recent report by Grimm et al [63] , which utilized measures (oddball, TMT) very similar to ours on The pre-rHuEPO treatment scores on the neuropsychological measures were quite similar to the scores reported on these tests in previously studied groups of stable CHD patients [5] [6] [7] [8] 11] . Current, age-adjusted norms [53, [64] [65] [66] indicate that the mean pretreatment scores fall at the seventh percentile (borderline range) for SDMT, the 16th percentile (low average) for RAVLT, the 46th percentile (average) for COWAT and the 14th percentile (low average) for TMTB. After 12 months of treatment, mean scores for all tests were within the average range: SDMT 30th percentile, RAVLT 51st percentile, COWAT 74th percentile, TMTB 32nd percentile. A number of inferences can be drawn from these comparisons with normative data. First, pre-treatment scores were at most only mildly impaired, a finding consistent with other reports that stable CHD patients T + 12 months manifest either normal functioning or mild to moderate impairment in selected areas of cognitive function [5] [6] [7] [8] 11] . Second, after 12 months of treatment all scores were well within the normal range. Third, those measures on which performance was most impaired before treatment (SDMT, TMTB) showed the greatest improvement with treatment. It is of interest that both tests share the requirement for frequent and rapid shifts in attention.
Both the SDMT and TMTB, the tests on which performance improved significantly with rHuEPO treatment, have been shown to be relatively insensitive to test-retest effects and stable over time [53, 67] . Thus, it is unlikely that the improvement can be attributed to practice effects.
The results of this study suggest some difference in the timing of ERP and neuropsychological test performance changes with rHuEPO treatment. P3 amplitude increased significantly alter three months of treatment and showed no significant change thereafter ( Table 2 ). This paralleled the course of hematocrit changes. SDMT also showed significant improvement after three months, and additional improvement at 12 months (Table  3 ). In contrast, TMTB time to completion showed only slight improvement after three months of treatment but significant s patient group comparable in age (51.5 years). While the basis or this discrepancy in findings is not yet clear, the P3 latency iata suggest that the patients in the Grimm et al [63] study may ave been more ill and perhaps more cognitively impaired than :hose we studied. Prior to treatment their patients had a mean P3 latency of 391 msec as compared to 332 msec for our atients, a difference of approximately 60 msec. Given the ;imilarity in paradigms, it would be expected that P3 latency for lormal subjects on both tasks would be approximately 330 28 nsec [28] . Thus, patients in the Grimm et al [63] study had P3 atencies more than 2 standard deviations beyond the expected lormal mean, while patients in our study had normal latencies.
Elence, it is possible that we did not observe consistent P3 atency changes because the majority of patients in our study lad normal P3 latencies before rHuEPO treatment. Despite the improvement at T + 12 months. Given our limited knowledge of the effects of anemia and its correction on brain and cognitive functions, we can only speculate concerning factors accounting for the difference in rate of change for electrophysiological and neuropsychological measures. One obvious possibility concerns level of task demand and complexity. Both SDMT and TMTB are complex tasks requiring sustained attention, rapid accurate scanning, psychomotor speed and memory. Compared to these measures, the oddball task used to elicit ERPs is much simpler and less demanding. It is conceivable that the effects of the correction of anemia may be immediately apparent in the less demanding cognitive functions subserving simple tasks but the more complex cognitive functions involved in demanding tasks may take longer to normalize. Moreover, ERPs appear to be less sensitive to such factors as mood or emotional state than is neuropsychological test performance. Though brain dysfunction has been known to occur in uremic patients for over 150 years, a comprehensive understanding of its pathogenesis is lacking. Initially, attention was focused on alterations in brain structure in uremia. The seminal study of Olsen [68] , while revealing multiple areas of neuronal degeneration in the brains of uremics who had died, failed to succeed in correlating these findings with the premorbid clinical signs and symptoms.
Many abnormalities of brain metabolism have also been described in the presence of uremia. These include decreased utilization of ATP [69] , lowered oxygen and energy con sumption [70] , decreased Na-K-ATPase activity [71] , increased brain calcium content [72] , altered brain cell permeability [73] and elevated CSF tryptophan [74] . Some of these abnormalities may be directly or indirectly caused by retained endogenous uremic toxins. Others might be related to hormonal abnormalities seen in uremia (such as hyperparathyroidism) or exogenous toxins (such as aluminum).
The results of the present study suggest that anemia can also affect brain function in uremic patients. There are at least two possible mechanisms for this effect that deserve further study. First, it has been shown that cerebral blood flow is increased above normal in uremics [75] ; this increase can be attributed to anemia. The high cerebral blood flow in the presence of anemia and uremia would result in a high delivery of uremic toxins to the brain. By treating the anemia and thus lowering cerebral blood flow, toxin delivery to the brain may be decreased and an improvement in CNS function would be expected, as we have seen. In this model, correction of anemia indirectly improves "brain uremia." If this mechanism is operative, it would be important to anemic uremics, but not generalizable to other anemic patients.
Although the prescribed dose of dialysis was kept constant in this study, both BUN and creatinine levels fell significantly after twelve months of rHuEPO treatment. There was no change in PCR (1.21 -1.20 glkg!day) or dry weight (60.3 kg -59.1 kg) suggesting maintenance of a stable muscle mass and state of nutrition. Though the change in BUN and creatinine may have further contributed to the amelioration of "brain uremia" described above, it does not account for the improvement in ERP and neuropsychological measures observed after three months of treatment. Secondly, the effect of correction of anemia in uremics might reflect a beneficial effect for patients with anemia of other causes. This would be the case if the effect seen was caused by the improved cerebral oxygen delivery associated with correction of anemia. Optimal brain oxygen delivery occurs at an hematocrit of -33% [14] . At levels below this oxygen delivery falls precipitously. The decreased oxygen delivery might impair a variety of brain metabolic functions as reflected in the electrophysiological and cognitive function tests reported in this study. Either or both of these mechanisms could have produced the attenuated P3 amplitudes observed in patients on dialysis for more than 50 months.
Though abnormalities of cerebral function have not been reported in anemic patients without uremia, systematic studies in this group of patients have not been conducted. Such studies would be important to help further our understanding of brain metabolism, its dependence on oxygen delivery, and the potential harmful effects of prolonged anemia on the brain.
Including this report, three recent studies have assessed the effects of rHuEPO treatment in renal patients stabilized on hemodialysis. All indicate that the correction of anemia improves aspects of brain/cognitive function. DiPaolo et al [76] and Grimm et al [63] report shortened latencies or increased amplitudes of EPs from somatosensory, auditory and visual pathways suggestive of more efficient functioning at the brainstem level. Both the Grimm et al study and ours find changes indicative of improvement in cognitive functioning in electrophysiological (P3) and neuropsychological measures. While the specific measures which show improvement vary across studies, results at this early stage of investigation point to significant improvement in brain and cognitive function with the correction of anemia by rHuEPO treatment.
